iPS Cells & Regenerative Medicine– category –
-
Imviva Biotech’s Off-the-Shelf Allogeneic CAR T Therapy CTD402 Achieves High Response Rates in Relapsed/Refractory T-ALL/LBL at EHA Presentation
GlobeNewswire (Imviva Biotech) USA Overview Imviva Biotech presented promising clinical data for its next-generation off-the-shelf allogeneic CAR T-cell therapy, CTD402, at the EHA 2026 annual meeting. The therapy targets adult and pedia... -
Fate Therapeutics Presents Positive Clinical and Preclinical Data for iPSC-Derived Off-the-Shelf CAR T Therapies FT819, FT839, and FT836 in Autoimmune Diseases and Solid Tumors
Fate Therapeutics USA Overview Fate Therapeutics unveiled updated clinical and preclinical data for its iPSC-derived off-the-shelf CAR T-cell programs at EULAR and in corporate presentations. The Phase 1 trial for anti-CD19 CAR T-cell th... -
Cellectis’ Lasme-cel Receives FDA RMAT Designation as First Allogeneic CAR T in Pivotal Trial for R/R B-ALL, EHA Data Confirms Efficacy
Stock Titan (Cellectis SEC Filing) USA Overview Cellectis announced that its CD22-targeting allogeneic CAR T-cell therapy candidate, lasme-cel (UCART22), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA... -
iPS Cells & Regenerative Medicine Weekly Report May 7, 2026
📄 Weekly Report June 07, 2026 (PDF) — Download Weekly Report June 07, 2026 (PDF) — DownloadDownload 🎙 Podcast June 07, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260607.mp3Download -
Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences
Stock Titan USA Overview Sana Biotechnology is scheduled to present its Q1 2026 financial results and recent business updates on its hypoimmune cell therapy and in vivo gene editing platforms at multiple investor conferences in June 2026... -
DelveInsight Reports Robust Parkinson’s Disease Pipeline: Over 240 Therapies in Clinical and Preclinical Development
DelveInsight USA Overview DelveInsight's "Parkinson's Disease Pipeline Analysis, 2026" reveals a highly active R&D landscape with over 240 therapies in clinical and preclinical stages. This extensive pipeline spans diverse modalities... -
Japan Reinforces LMO Safety Regulations for Advanced Biotech Research and Regenerative Medicine
厚生労働省 Japan Overview Japan's Ministry of Health, Labour and Welfare (MHLW) has reissued critical guidelines on the contained use (Type 2) of living modified organisms (LMOs) under the Cartagena Act. This re-notification emphasizes s... -
DelveInsight: 180+ Companies Propel CAR-T Innovation, Forging a New Era in Cell Therapy
DelveInsight USA Overview A new DelveInsight report reveals the significant expansion of the CAR-T cell therapy pipeline, with over 180 companies driving innovation. Projecting substantial market growth by 2036, the report highlights key... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ... -
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a...
